Navigation Links
Optimal vitamin D dosage for infants uncertain
Date:4/30/2013

dings of this study in an accompanying editorial.

"The data reported by Gallo et al do not answer the question of what the target should be for plasma 25(OH)D concentration. If the target is 75 nmol/L or higher, then vitamin D intake of 400 IU/d is not enough for a substantial proportion of infants, especially those in northern parts of the United States or in Canada or who have darker skin pigmentation. However, another question that needs to be answered is whether there are non-bone health reasons to target a plasma 25(OH)D concentration greater than 75 nmol/L. Answering such questions about non-bone health aspects of vitamin D nutrition can be accomplished only by rigorous clinical trials that include enough participants and establish clear outcomes before the study begins."

"Pending such information, clinicians can be reassured by the findings from the study by Gallo et al that a daily vitamin D intake of 400 IU/d in infants, as currently recommended, leads to adequate plasma 25(OH)D concentration for identified physiological functioning related to bone health."

(JAMA. 2013;309(17):1830-1831; Available pre-embargo to the media at http://media.jamanetwork.com)

Editor's Note: Please see the article for additional information, including financial disclosures, funding and support, etc.


'/>"/>

Contact: Hope Weiler
hope.weiler@mcgill.ca
The JAMA Network Journals
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. UNC Charlotte researcher leads effort to forecast optimal energy investments
2. Vitamin E identified as potential weapon against obesity
3. Quit smoking? Vitamin E may give extra boost to heart health
4. Excess vitamin E intake not a health concern
5. Vitamin P as a potential approach for the treatment of damaged motor neurons
6. Vitamin D benefits breathing in tuberculosis patients
7. Living in a sunny climate does not improve vitamin D levels in hip fracture patients
8. Folate and vitamin B12 reduce disabling schizophrenia symptoms in some patients
9. Organic tomatoes accumulate more vitamin C, sugars than conventionally grown fruit
10. Vitamin C is beneficial against the common cold
11. African-American, Caucasian women should take identical vitamin D doses
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/13/2015)... According to a recently ... & Opportunities, 2020", the global biometrics market is ... till 2020. The biometrics market is garnering attention ... review of biometric management systems. The constant development ... greater efficiency, are resulting in increasing installation of ...
(Date:4/10/2015)... Research and Markets ( http://www.researchandmarkets.com/research/cjk4gb/security ... Competitive Profiles - NEC" report to their offering. ... will continue to supply a range of IT security ... company focus on the development of a Big Data ... in the Asia-Pacific region is ...
(Date:4/8/2015)... N.C. , April 8, 2015  Infinisource, ... solutions and services, and Morpho, a leading supplier ... partnership to produce the market,s most advanced biometrically-enabled ... Infinisource,s iSolved NXG time clock is setting a ... and labor data for the small and mid-size ...
Breaking Biology News(10 mins):Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2NEC Security Competitive Profile 2015 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3
... NEW YORK and LEON, GUANAJUATO MEXICO, Aug. 18 ... control and identity management market, announced today that it ... in Leon, Guanajuato, Mexico. Portoss, a Leon-based company, specializes ... This latest partnership between Portoss and the City of ...
... AMES - A special set of sugars found ... body,s natural defenses as well as vaccines, say two ... a first step in understanding a disease family that ... vaccines or cures. Nicola Pohl, professor of chemistry, ...
... In findings that push back the clock on the ... Earth, Princeton scientists may have discovered the oldest fossils ... living in ocean reefs about 650 million years ago. ... deposit in South Australia, represent the earliest evidence of ...
Cached Biology News:Global Rainmakers Delivers World Class Iris Capability for Portoss 2Global Rainmakers Delivers World Class Iris Capability for Portoss 3ISU researchers discover cause of immune system avoidance of certain pathogens 2ISU researchers discover cause of immune system avoidance of certain pathogens 3Possible discovery of earliest animal life pushes back fossil record 2Possible discovery of earliest animal life pushes back fossil record 3Possible discovery of earliest animal life pushes back fossil record 4
(Date:5/21/2015)... 2015  CytRx Corporation (NASDAQ: CYTR ), ... oncology, today announced positive updated results from its ... the treatment of unresectable glioblastoma multiforme (GBM), a ... trial is designed to investigate the preliminary efficacy ... have progressed following prior treatment with surgery, radiation ...
(Date:5/21/2015)... Tunnell Consulting, Inc. today ... senior statistician and Principal, a position to which she ... management and analysis of complex and large data sets ... “We’re delighted to have Julia join the Tunnell team ... Dr. Philippe Cini, Group Vice President and leader of ...
(Date:5/20/2015)... 20, 2015  Select Medical Corporation ("Select") (NYSE: ... Commission granted early termination of the waiting period ... 1976, as amended, applicable to the acquisition of ... joint venture that Select has created with Welsh, ... previously announced, MJ Acquisition Corporation has signed a ...
(Date:5/20/2015)... Mass. , May 20, 2015  Haemonetics Corporation ... Concannon , President & CEO, will present at The ... York on June 1 st , 2015 ... may access Mr. Concannon,s presentation live via webcast at: ... Haemonetics (NYSE: HAE ) is a global ...
Breaking Biology Technology:CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7Julia O’Neill Joins Tunnell Consulting’s Operational and Process Improvement Practice 2Select Medical Corporation's Proposed Acquisition of Concentra Inc. through Joint Venture with Welsh Carson Receives Antitrust Clearance 2
... is to make a major contribution to our fuel supplies, ... insect helpers, says Michael Scharf, an assistant professor of entomology ... review to be published in Biofuels, Bioproducts & Biorefining ... enzymes produced by both termites and the micro-organisms that inhabit ...
... Oct. 21 Boston Scientific,Corporation (NYSE: BSX ) today ... as well as guidance for net sales and,earnings per share ... quarter highlights: -- Reported net sales of $1.978 billion ... stent (DES) market leadership -- Achieved worldwide cardiac rhythm ...
... to Pay Amylin $125 Million and Extend $165 Million Line of Credit to ... ... 21 Amylin,Pharmaceuticals, Inc. (Nasdaq: AMLN ) and Eli Lilly and Company ... for,exenatide once weekly, a development compound that, if approved, would,become the first once ...
Cached Biology Technology:Digesting the termite digestome -- a way to make biofuels? 2Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 2Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 3Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 4Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 5Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 6Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 7Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 8Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 9Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 10Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 11Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 12Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 13Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 14Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 15Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 16Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 17Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 18Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 19Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 20Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 21Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 22Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 23Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 24Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 25Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 26Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 27Lilly and Amylin Enter Into Supply Agreement for Exenatide Once Weekly 2Lilly and Amylin Enter Into Supply Agreement for Exenatide Once Weekly 3
... Monoclonal to L1 Cell Adhesion Molecule ... located in Xq28, is involved in three ... aqueduct of Sylvius); 2) MASA (mental retardation, ... SPG1 (spastic paraplegia). Immunogen: ...
...
Immunogen: C terminus [VQLKRSKNDSKPYC] of cardiac elav-type RNA-binding protein (ETR-3) Storage: -20 C, Avoid Freeze/Thaw Cycles...
Human ABCG2 MAb (Clone 5D3)...
Biology Products: